$473 Million is the total value of BROADWOOD CAPITAL INC's 6 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNST | MONSTER BEVERAGE CORP | $146,593,000 | +29.1% | 1,599,136 | 0.0% | 30.98% | +49.5% | |
| STAA | STAAR SURGICAL CO | $73,210,000 | -36.7% | 6,887,095 | 0.0% | 15.47% | -26.7% | |
| CYNO | CYNOSURE INCcl a | $17,158,000 | -1.2% | 817,029 | 0.0% | 3.63% | +14.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STAAR SURGICAL CO | 45 | Q2 2024 | 59.1% |
| MONSTER BEVERAGE CORP NEW | 37 | Q2 2024 | 49.7% |
| ISHARES TR | 36 | Q2 2024 | 14.8% |
| ONCOCYTE CORPORATION | 31 | Q2 2023 | 4.6% |
| AXON ENTERPRISE INC | 27 | Q2 2024 | 17.9% |
| BIOTIME INC | 25 | Q2 2019 | 17.8% |
| AGEX THERAPEUTICS INC | 21 | Q4 2023 | 1.5% |
| LINEAGE CELL THERAPEUTICS INC | 20 | Q2 2024 | 5.1% |
| ASTERIAS BIOTHERAPEUTICS INC | 16 | Q4 2018 | 2.9% |
| CYNOSURE INC | 15 | Q4 2016 | 10.4% |
View BROADWOOD CAPITAL INC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 4 | 2024-04-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-11-30 |
View BROADWOOD CAPITAL INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.